Ghiaseddin, Ashley P. http://orcid.org/0000-0001-5599-4610
Shin, David
Melnick, Kaitlyn
Tran, David D.
Article History
First Online: 30 July 2020
Compliance with Ethical Standards
:
: Ashley P. Ghiaseddin has received research funding from Orbus Therapeutics and has received compensation from Novocure and Monteris Medical for participation on medical advisory boards.David Shin declares that he has no conflict of interest.Kaitlyn Melnick declares that she has no conflict of interest.David D. Tran has received research funding from Novocure, Lacerta Therapeutics, Merck, Novartis, Monteris Medical, Tocagen, Advanced BioScience Laboratories (ABL), and Stemline Therapeutics; has received compensation from Novocure and Monteris Medical for participation on medical advisory boards; has received reimbursement for travel expenses from Novartis; and has the following patents pending:*“Inhibiting Prostaglandin E Receptor 3 Resensitizes Resistant Cells to TTFields”*“Methods for Reducing Viability of Cancer Cells by Activation of the STING Pathway with TTFields”*“AAV capsid variants targeting human glioblastoma stemlike cells” (licensed to Lacerta Therapeutics)*“Core Master Regulators of Glioblastoma Stem Cells”*“Methods for Targeted Treatment and Prediction of Patient Survival in Cancer”*“Methods for Cancer Screening and Monitoring by Cancer Master Regulators Markers in Liquid Biopsy”*“Immunotherapy for Direct Reprogramming of Cancer Cells into Immune Cells/Antigen Presenting Cells/Dendritic Cells”<sup>*</sup>“GeneRep and nSCORE: Method and Apparatus for Improved Determination of Node Influence in a Network”
Free to read: This content has been made available to all.